Viamet Pharmaceuticals

Durham, NC

CEO: Bob Schotzinger

Viamet is a biotechnology company discovering and developing inhibitors of validated metalloenzymes via a proprietary metal-binding approach. The company’s technology identifies validated targets with high therapeutic and commercial potential, leverages existing metalloenzyme inhibitors as the basis for best-in-class analogs and generates small molecule compounds by optimizing the metal-binding component of existing inhibitors.